News | July 07, 2023
Dabur India expects 10%+ consolidated growth in Q1 FY24
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Dignitaries and delegates commend India’s leadership in Global South during G20 India Presidency
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Construction will begin this year with the new capacity anticipated by 2025
The company reported lifetime high EBIDTA of Rs. 250 crores
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Subscribe To Our Newsletter & Stay Updated
